Yogurt Products Deviating From Standard of Identity; Temporary Permit for Market Testing, 18322-18323 [2023-06390]
Download as PDF
<![CDATA[
18322
Federal Register / Vol. 88, No. 59 / Tuesday, March 28, 2023 / Notices
including selecting an appropriate
animal model; study monitoring; and
study evaluation. The document also
provides recommendations on test
facility selection, animal housing, and
records and reports, including animal
study reports for premarket
submissions. This guidance supersedes
the final guidance ‘‘General
Considerations for Animal Studies for
Cardiovascular Devices,’’ issued on July
28, 2010.
A notice of availability of the draft
guidance appeared in the Federal
Register of October 14, 2015 (80 FR
61820). FDA considered comments
received and revised the guidance as
appropriate in response to the
comments, including increased
emphasis of the 3Rs to reduce, refine,
and replace animal use in testing when
feasible, reorganization of the guidance
to better represent the study design,
conduct, and reporting process,
clarification of important terminology,
and technical edits.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on general
considerations for animal Studies
intended to evaluate medical devices. It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
II. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/medical-devices/
device-advice-comprehensiveregulatory-assistance/guidancedocuments-medical-devices-andradiation-emitting-products. This
guidance document is also available at
https://www.regulations.gov or https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents.
III. Paperwork Reduction Act of 1995
While this guidance contains no new
collection of information, it does refer to
previously approved FDA collections of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501–
3521) is not required for this guidance.
The previously approved collections of
information are subject to review by
OMB under the PRA. The collections of
information in the following FDA
regulations, guidance, and forms have
been approved by OMB as listed in the
following table:
OMB
control No.
21 CFR part; guidance; or FDA form
Topic
807, subpart E ............................................................................
814, subparts A through E .........................................................
814, subpart H ............................................................................
812 ..............................................................................................
‘‘De Novo Classification Process (Evaluation of Automatic
Class III Designation)’’.
‘‘Requests for Feedback on Medical Device Submissions: The
Pre-Submission Program and Meetings with Food and Drug
Administration Staff’’.
820 ..............................................................................................
Premarket notification .................................................................
Premarket approval ....................................................................
Humanitarian Device Exemption ................................................
Investigational Device Exemption ..............................................
De Novo classification process ..................................................
0910–0120
0910–0231
0910–0332
0910–0078
0910–0844
Q-submissions ............................................................................
0910–0756
Current Good Manufacturing Practice (CGMP); Quality System
(QS) Regulation.
Good Laboratory Practice (GLP) Regulations for Nonclinical
Laboratory Studies.
0910–0073
58 ................................................................................................
Dated: March 21, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–06254 Filed 3–27–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0853]
lotter on DSK11XQN23PROD with NOTICES1
Persons unable to download an
electronic copy of ‘‘General
Considerations for Animal Studies
Intended to Evaluate Medical Devices’’
may send an email request to CDRHGuidance@fda.hhs.gov to receive an
electronic copy of the document. Please
use the document number GUI00001802
and complete title to identify the
guidance you are requesting.
Yogurt Products Deviating From
Standard of Identity; Temporary Permit
for Market Testing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
SUMMARY:
VerDate Sep<11>2014
16:59 Mar 27, 2023
Jkt 259001
announcing that we have issued a
temporary permit to Chobani, LLC (the
applicant) to market test lower fat
yogurt products deviating from the
general definition and standard of
identity for yogurt with modified
milkfat and fat-containing flavoring
ingredients, and yogurt deviating from
the yogurt standard of identity by using
ultrafiltered nonfat milk as a basic dairy
ingredient. The temporary permit will
allow the applicant to evaluate
commercial viability of the products
and to collect data on consumer
acceptance of the products.
This temporary permit is
effective for 15 months, beginning on
the date the applicant introduces or
causes introduction of the test products
into interstate commerce, but not later
than June 26, 2023.
DATES:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
0910–0119
FOR FURTHER INFORMATION CONTACT:
Marjan Morravej, Center for Food Safety
and Applied Nutrition (HFS–820), Food
and Drug Administration, 5001 Campus
Dr., College Park, MD 20740, 240–402–
2371.
SUPPLEMENTARY INFORMATION: We are
giving notice that we have issued a
temporary permit to Chobani, LLC. We
are issuing the temporary permit in
accordance with 21 CFR 130.17, which
addresses temporary permits for
interstate shipments of experimental
packs of food varying from the
requirements of definitions and
standards of identity issued under
section 401 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 341).
The temporary permit covers
interstate market testing of the yogurt
products. The test products deviate from
the basic dairy ingredient provision of
the yogurt standard of identity (21 CFR
E:\FR\FM\28MRN1.SGM
28MRN1
Federal Register / Vol. 88, No. 59 / Tuesday, March 28, 2023 / Notices
131.200(b)). This temporary permit
would allow the applicant to
manufacture yogurts using ultrafiltered
nonfat milk as a basic dairy ingredient
through the addition of water and nonnutritive sweeteners. Consumers can
distinguish this deviation in
manufacturing from yogurts meeting the
standard of identity for yogurt using the
list of ingredients, wherein the
‘‘ultrafiltered nonfat milk’’ ingredient
would be declared as such according to
its common or usual name followed by
a means to indicate to the consumer that
the ingredient is not found in regular
yogurt consistent with 21 CFR
130.10(g)(2).
The purpose of the temporary permit
is to allow the applicant to market test
the products throughout the United
States. The temporary permit will allow
the applicant to evaluate commercial
viability of the products and to collect
data on consumer acceptance of the
products.
This temporary permit provides the
temporary marketing of a maximum of
150,000,000 pounds (68,038,855.5
kilograms) of the test products. Chobani,
LLC will manufacture the test products
at its facilities located at 3450 Kimberly
Rd. East, Twin Falls, ID 83301 and 669
County Rd. 25, New Berlin, NY 13411.
Chobani, LLC will produce, market test,
and distribute the test products
throughout the United States.
Each ingredient used in the food must
be declared on the labels as required by
the applicable sections of 21 CFR part
101. This temporary permit is effective
for 15 months, beginning on the date the
applicant introduces or causes the
introduction of the test products into
interstate commerce, but not later than
June 26, 2023.
Dated: March 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–06390 Filed 3–27–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
OWH Observance Champions;
Correction
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice; correction.
lotter on DSK11XQN23PROD with NOTICES1
AGENCY:
The Office of the Assistant
Secretary for Health published a
document in the Federal Register of
September 14, 2022, inviting public and
private sector organizations to apply to
SUMMARY:
VerDate Sep<11>2014
16:59 Mar 27, 2023
Jkt 259001
become a Women’s Health Champion.
The document includes contact
information for a staff member who is
no longer working in the Office on
Women’s Health.
SUPPLEMENTARY INFORMATION:
Correction
In the Federal Register of September
14, 2022, in FR Doc. 2022–19839, on
page 56426, correct the For further
information contact caption to read:
FOR FURTHER INFORMATION CONTACT:
Gabriella Forte. Office on Women’s
Health, Office of the Assistant Secretary
for Health, U.S. Department of Health
and Human Services; 1101 Wootton
Parkway, Rockville, MD 20852;
Telephone: 202–690–7650. Email:
Womenshealth@hhs.gov.
Dated: March 20, 2023.
Richelle Marshall,
Deputy Director for Operations and
Management, Office of the Assistant Secretary
for Health, Office on Women’s Health.
18323
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Virtual
Assessments of Children and Caregivers.
Date: May 2, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jeanne M. McCaffery,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–3854,
jeanne.mccaffery@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 23, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–06404 Filed 3–27–23; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2023–06319 Filed 3–27–23; 8:45 am]
BILLING CODE 4150–33–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Basic
Cancer Immunology.
Date: April 27, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sarita Kandula Sastry,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20782, 301–402–4788, sarita.sastry@nih.gov.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer
Etiology.
Date: April 11, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sarita Kandula Sastry,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20782, 301–402–4788, sarita.sastry@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 88, Number 59 (Tuesday, March 28, 2023)]
[Notices]
[Pages 18322-18323]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06390]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0853]
Yogurt Products Deviating From Standard of Identity; Temporary
Permit for Market Testing
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that we have issued a temporary permit to Chobani, LLC (the applicant)
to market test lower fat yogurt products deviating from the general
definition and standard of identity for yogurt with modified milkfat
and fat-containing flavoring ingredients, and yogurt deviating from the
yogurt standard of identity by using ultrafiltered nonfat milk as a
basic dairy ingredient. The temporary permit will allow the applicant
to evaluate commercial viability of the products and to collect data on
consumer acceptance of the products.
DATES: This temporary permit is effective for 15 months, beginning on
the date the applicant introduces or causes introduction of the test
products into interstate commerce, but not later than June 26, 2023.
FOR FURTHER INFORMATION CONTACT: Marjan Morravej, Center for Food
Safety and Applied Nutrition (HFS-820), Food and Drug Administration,
5001 Campus Dr., College Park, MD 20740, 240-402-2371.
SUPPLEMENTARY INFORMATION: We are giving notice that we have issued a
temporary permit to Chobani, LLC. We are issuing the temporary permit
in accordance with 21 CFR 130.17, which addresses temporary permits for
interstate shipments of experimental packs of food varying from the
requirements of definitions and standards of identity issued under
section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
341).
The temporary permit covers interstate market testing of the yogurt
products. The test products deviate from the basic dairy ingredient
provision of the yogurt standard of identity (21 CFR
[[Page 18323]]
131.200(b)). This temporary permit would allow the applicant to
manufacture yogurts using ultrafiltered nonfat milk as a basic dairy
ingredient through the addition of water and non-nutritive sweeteners.
Consumers can distinguish this deviation in manufacturing from yogurts
meeting the standard of identity for yogurt using the list of
ingredients, wherein the ``ultrafiltered nonfat milk'' ingredient would
be declared as such according to its common or usual name followed by a
means to indicate to the consumer that the ingredient is not found in
regular yogurt consistent with 21 CFR 130.10(g)(2).
The purpose of the temporary permit is to allow the applicant to
market test the products throughout the United States. The temporary
permit will allow the applicant to evaluate commercial viability of the
products and to collect data on consumer acceptance of the products.
This temporary permit provides the temporary marketing of a maximum
of 150,000,000 pounds (68,038,855.5 kilograms) of the test products.
Chobani, LLC will manufacture the test products at its facilities
located at 3450 Kimberly Rd. East, Twin Falls, ID 83301 and 669 County
Rd. 25, New Berlin, NY 13411. Chobani, LLC will produce, market test,
and distribute the test products throughout the United States.
Each ingredient used in the food must be declared on the labels as
required by the applicable sections of 21 CFR part 101. This temporary
permit is effective for 15 months, beginning on the date the applicant
introduces or causes the introduction of the test products into
interstate commerce, but not later than June 26, 2023.
Dated: March 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-06390 Filed 3-27-23; 8:45 am]
BILLING CODE 4164-01-P
